Phage infection of bacterial biofilm
This project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections.
Projectdetails
Introduction
In 2017, the World Health Organization declared Staphylococcus aureus to be an antibiotic-resistant pathogen for which new therapeutics are urgently needed. Upon infection, S. aureus forms biofilms that can only be treated by the long-term application of several antibiotics in high doses or the surgical removal of the infected tissues.
Alternative Approaches
An alternative approach, phage therapy, has not been approved for clinical use because the effects of phage infection on a biofilm are not sufficiently characterized. We propose to study the dynamics of the propagation of Herelleviridae phage phi812 in a S. aureus biofilm and the molecular details of phi812 replication in a cell.
Methodology
We integrated a microfluidic system into a light-sheet microscope to enable continuous multi-day observation of the phage infection of a biofilm. Our research will focus on the following aspects:
- Determining how sub-populations of metabolically dormant or phage-resistant cells in a biofilm provide herd immunity against phi812 infection.
- Fixing biofilm segments for subsequent correlative imaging by serial block-face scanning electron microscopy to identify the interactions of phages with bacterial cells.
- Using focused ion beam milling together with cryo-electron microscopy and tomography to determine high-resolution structures of previously uncharacterized phi812 replication and assembly intermediates in S. aureus cells.
Biological Significance
We will study the function of bacterial membranes and macromolecular complexes in the initiation and completion of phage genome delivery, the assembly of phage portal complexes and heads, and the mechanisms of genome packaging and head-tail attachment.
This proposal's biological significance lies in its focus on the as-yet uncharacterized interactions of phages and bacteria under biologically and clinically relevant conditions. Our analyses of phage spread in a biofilm, herd immunity against phage infection, and phage replication in cells may identify approaches for making phage therapy more effective.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.992.976 |
Totale projectbegroting | € 1.992.976 |
Tijdlijn
Startdatum | 1-1-2023 |
Einddatum | 31-12-2027 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- Masarykova univerzitapenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered ProphagesPHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine. | ERC Starting... | € 1.500.000 | 2025 | Details |
Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phagesThis project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions. | ERC Starting... | € 1.499.250 | 2024 | Details |
Modification of liposomic nano-carriers: a novel strategy for improved drug-delivery and eradication of bacterial biofilmsThis project aims to develop and evaluate a novel drug delivery system to effectively treat and eradicate bacterial biofilms, addressing significant health and economic challenges. | ERC Proof of... | € 150.000 | 2022 | Details |
Life of Giant PhagesThis project aims to isolate and study giant phages from boreal freshwaters to understand their structure, host interactions, and ecological roles, advancing phage biology and microbial ecology. | ERC Starting... | € 1.499.808 | 2023 | Details |
Phage co-infection: a missing link in deciphering phage co-evolutionary dynamicsMULTIPHAGE aims to revolutionize our understanding of phage genome evolution by investigating co-infection dynamics through innovative omics methods and structural phylogeny. | ERC Starting... | € 1.499.401 | 2024 | Details |
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages
PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.
Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phages
This project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions.
Modification of liposomic nano-carriers: a novel strategy for improved drug-delivery and eradication of bacterial biofilms
This project aims to develop and evaluate a novel drug delivery system to effectively treat and eradicate bacterial biofilms, addressing significant health and economic challenges.
Life of Giant Phages
This project aims to isolate and study giant phages from boreal freshwaters to understand their structure, host interactions, and ecological roles, advancing phage biology and microbial ecology.
Phage co-infection: a missing link in deciphering phage co-evolutionary dynamics
MULTIPHAGE aims to revolutionize our understanding of phage genome evolution by investigating co-infection dynamics through innovative omics methods and structural phylogeny.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
in silico bio-evolutio - novel AI paradigm for molecular biologyThis project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness. | EIC Accelerator | € 1.692.596 | 2023 | Details |
Behandeling van antibioticaresistente S. aureus en preventie van verdere antibioticaresistentieHet project onderzoekt de haalbaarheid van een op antilichamen gebaseerd product voor de behandeling van S. aureus-infecties, gericht op genezing en het voorkomen van antibioticaresistentie. | Mkb-innovati... | € 20.000 | 2021 | Details |
Fast, easy diagnostics for personalised phage therapyVésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours. | EIC Accelerator | € 1.800.000 | 2023 | Details |
Advanced nanomaterials to target genomic and Z-DNA for bacterial biofilm eradicationBactEradiX aims to create a novel antimicrobial nanomaterial targeting biofilm Z-DNA to effectively eradicate chronic infections caused by drug-resistant bacteria. | EIC Pathfinder | € 2.996.312 | 2024 | Details |
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
in silico bio-evolutio - novel AI paradigm for molecular biology
This project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness.
Behandeling van antibioticaresistente S. aureus en preventie van verdere antibioticaresistentie
Het project onderzoekt de haalbaarheid van een op antilichamen gebaseerd product voor de behandeling van S. aureus-infecties, gericht op genezing en het voorkomen van antibioticaresistentie.
Fast, easy diagnostics for personalised phage therapy
Vésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours.
Advanced nanomaterials to target genomic and Z-DNA for bacterial biofilm eradication
BactEradiX aims to create a novel antimicrobial nanomaterial targeting biofilm Z-DNA to effectively eradicate chronic infections caused by drug-resistant bacteria.
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.